Atrium Therapeutics has dosed the first patient in its Phase 1/2 Corventis trial testing ATR 1072 for PRKAG2 syndrome, a rare genetic heart condition. Nonclinical data showed ATR 1072 reversed harmful cardiac glycogen buildup and improved heart function markers. The company raised $50 million in a private placement, boosting its cash balance to $293.6 million and securing funding through 2028. Initial trial results are expected in the second half of 2027, with further pipeline advancements planned.
Atrium Therapeutics' recent developments provide context for health-sector market activity on Pluang as of Nov 13, 2026 04:11 WIB. Among 150 priced health-sector US stocks, only 23 rose while 124 fell. Notably, CTXR gained 11.19% at USD 0.53 with 84% sell orders, contrasting with SANA's 11.79% drop to USD 2.02 and 60% buy orders, and SMMT's 9.25% decline to USD 15.10 with 57% buy activity. Typical hold times ranged from 19 to 26 days across these movers.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
